Brain MRI and biological diagnosis in five Tunisians MLD patients
© Barboura et al; licensee BioMed Central Ltd. 2012
Received: 25 September 2011
Accepted: 28 January 2012
Published: 28 January 2012
Metachromatic leukodystrophy (MLD) is a recessive autosomal disease which is characterized by an accumulation of sulfatides in the central and peripheral nervous system. It is due to the enzyme deficiency of the sulfatide sulfatase i.e. arylsulfatase A (ASA). we studied 5/200 cases of MLD and clearly distinguished three clinical forms. One of them presented the juvenile form; two presented the late infantile form; and two other presented the adult form. The Magnetic Resonance Imaging (MRI) of these patients showed a diffuse, bilateral and symmetrical demyelination. The biochemical diagnosis of MLD patients evidencing the low activity of ASA and sulfatide accumulation.
Patients and methods
We studied 5/200 MLD patients addressed to us for behavioral abnormalities and progressive mental deterioration. All of them were diagnosed at first by brain MRI evidencing a bilateral demyelination, then the measurement of ASA activity using P-nitrocathecol sulfate as substrate, finally the sulfatiduria was performed using thin-layer chromatography using alpha-naphtol reagent.
In this study, from 200 patients presenting behavioral abnormalities and a progressive mental deterioration, we reported just 2 patients were diagnosed as late-infantile form of MLD. Only1 case presented as the juvenile form; and 2 patients with the adult-type of MLD. The brain magnetic resonance imaging (MRI) of all patients showed characteristic lesions of MLD with extensive demyelination. Biochemical investigations of these patients detected a low level of ASA activity at 0°C and 37°C; the excess of sulfatide in sulfatiduria.
MRI is required to orient the diagnosis of MLD patients; the latter must be confirmed by the biochemical investigations which is based on the measurement of ASA activity and the excess of sulfatide showed in the sulfatiduria.
The virtual slide(s) for this article can be found here:
Keywordsarylsulfatase A urinary sulfatide sulfatide demylinisation metachromatic leukodystrophy
Metachromatic leukodystrophy or scholz's disease is an autosomal recessively inherited lysosomal storage disorder caused by the deficiency of arylsulfatase A (ASA). This enzyme catalyses the first degradation step of the glycosphingolipid 3-O-sulfogalactosylceramide (sulfatide). Sulfatide accumulates in white matter of the central nervous system and peripheral nerves as a result of ASA deficiency and leads to progressive demyelination and lethal neurological symptoms. Visceral organs with an excretory function such a kidney and gallbladder also store sulfatide but not so much affected functionally .
MLD is divided into three major clinical forms according to the age of onset. The most frequent and fatal form is the late-infantile form which starts before 4 years of age and patients die by the end of the first decade. The juvenile form of MLD includes age onset between 4 and 16 years, while symptoms of adult MLD start after puberty. In a few patients, MLD results from deficiency of the activator protein saposin B (SAP-B) .
For many years, since the discovery of the defect in ASA for MLD, and the easy enzymatic detection of ASA deficiency, this disease has been considered as affecting only children at the walking period, this neuropathology is characterized by a regression of previous acquisitions related to dys and demyelination . More precise data on the topographical sequences of myelination in humans has been recently developed by Magnetic Resonance Imaging.
The aim of this study is to underline the value of MRI for MLD diagnosis orientation and the interest of the biochemical study that involves the measurement of ASA activity and sulfatiduria to confirm MLD diagnosis.
Patients and methods
The patients in this study were unrelated and originated from different geographic areas of Tunisia. This study was approved by ethics committees of the respective Tunisian hospitals, and the families gave informed consent before withdrawal of blood. The studied patients were addressed to us for behavioral abnormalities and a progressive mental deterioration. The patients were always consanguineous.
Description of the 5 MLD patients.
Consanguinity of the parents/degree
Age of diagnosis (yr)
Age of onset (yr)
Died at 44 yr
ASA activity at 37°C (UV: 12-35 μkat/Kg of Proteine)
ASA activity at 0°C (UV: 3-9 μkat/Kg of Proteine)
Presence of an abnormal band of 3-O-sulfogalactosylceramide (sulfatide)
Cases with late-infantile form
This girl of 2 years was referred to the pediatric department of Nabeul hospital in the northern-west region of Tunisia. She was diagnosed as late infantile MLD; she had the same symptoms as the previous case, difficulty in walking, spontaneous contraction at extremities. She also had mental-motor retardation with low ASA activity and the chromatographic profile of sulfatiduria revealed the same excess of sulfatides showed in the first case. Her brain MRI showed the same lesions demonstrated in the first patient; Figure 1 and Figure 2.
Case with juvenile form
Cases with adult form
A 34-year-old female was referred to the neurological department of Fattouma Bourguiba Hospital of Monastir (Sahel). She presented both mental deterioration and behavioural modifications at the onset of the disease. These modifications lead her to psychiatric institutions. During evolution, other modifications appeared such as memory dysfunction, ideation difficulties, spatio-temporal disorientation, and loss of sense of judgement. The brain MRI showed the same lesions of the patient S.F; Figure 4. During evolution, the patient had increased motor and cerebellar symptoms. This lead to biological investigations, her ASA activity was low and her sulfatiduria showed the same abnormal band of sulfatide like the other patients; Figure 1.
ASA activity determination in leukocytes
ASA was determined in leukocytes which were isolated from blood samples of patients and homogenized by three times of freeze-thawing . Proteins were determined in leukocytes homogenates according to the method of lowry using bovine serum albumin as standard. ASA activity was determined in leukocyte homogenates that contain 100-400 μg protein using p-nitrocathecol sulfate (sigma Chemical Co.,USA) as substrate .
The excess of sulfatides must be evidenced to confirm the diagnosis as there are pseudo-deficiencies of ASA: it was either detected on a peripheral nerve biopsy showing characteristic metachromatic deposits, or more easily looking for sulfatiduria in urine .
This method was performed as followed: a 10 ml fresh urine sample was collected; 2 drops of concentrated acetic acid were added, after that the sample was left overnight in the cold; the pellet obtained after centrifugation 10 min at 2500 rpm, was collected and extracted by 5 ml chloroform/methanol 2:1 (v/v). After sonication, 1 ml distilled water was added; after mixing throughly and centrifugation, the upper phase contained urinary salts, and the lower phase, the lipid extract. The latter was evaporated to dryness and redissolved in 100 μl of chloroform:methanol 2:1for chromatography on silica-gel thin-later plates in chloroform:methanol:water 70:30:4 by volume; the revelation of the sulfatide glycolipid was done using alphanaphtol reagent [7, 8].
In This study, we estimated for the first time in Tunisia, the incidence of this neuropathology in our studied population; we founded just 5/200 cases representing the three MLD phenotypes. All suspected patients have a collapsed ASA activity in leukocyte homogenate and their chromatographic profiles were similar and revealed the presence of an abnormal band corresponding to the excess of 3-O-sulfogalactosylceramide and their brain MRI showed characteristics lesions of the three MLD forms in the white matter.
The MLD is a lysosomal storage disease, resulting mainly from ASA deficiency which is essential for the degradation of sulfatides. Three clinical forms have been described: the infantile form, the juvenile form and the adult form. The disparity of these phenotypes reflects the difficulty of the clinical, biological and paraclinical diagnostic. The study of heterozygous subjects by determination of enzyme activity is limited because there is an overlap between the values of ARSA activity in normal subjects and heterozygous . In some clinically healthy subjects or suffering from other neurological diseases than the MLD, enzyme activity observed may be collapsed, associated with PD alleles. These alleles represent 7-15% of alleles in the general population. PD in the ARSA must be recognized to avoid misdiagnosis and for prenatal diagnosis in families which coexists one allele of MLD .
The prenatal diagnosis is the best way to put heterozygous couple to the disease, especially in a couple who had an affected child (index case). Currently, the identification of fetal genotype and predicting the type of the disease even in the absence of family history has become easier with the use of molecular technologies . It is important to note that molecular diagnosis of MLD is more accurate and uses sample more stable than those used for determining enzyme activity. A molecular study is necessary to screen for the mutations causing different forms of this neuropathology. The characterization of these mutations allows us to clarify the genotype/phenotype correlations, to improve the quality of genetic counseling .
The conventional therapeutic approaches are essentially symptomatic. They were made in order to restore the arylsulfatase A activity and prevent the progression of the pathological accumulation of sulfatides and consequently reduce morbidity associated with MLD. The aim of enzymatic therapy is to administer MLD patient with active enzyme, this approach will be the future of metachromatic leukodystrophy .
The lysosomal storage diseases, especially the sphingolipidoses, presented a great clinical variability which complicated the diagnosis. According this study, the brain magnetic resonance imaging (MRI) was required to orient the diagnosis of MLD patients. The biochemical investigations such as the measurement of ASA activity and qualitative sulfatiduria were necessary to confirm MLD diagnosis. It is important to note that according this work, we estimated for the first time in Tunisia, the incidence of this neuropathology in our studied population; we found just 5/200 cases representing the three phenotypes of MLD.
List of abbreviations
magnetic resonance imaging.
We would like to extend our gratitude and thanks to Dr Abdelhedi Miled and Pr.Ag Ferchichi Salima for their help and collaborations throughout this work.
- Von Figura K, Gieselmann V, Jaeken J: Metachromatic leukodystrophy. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. 2001, New York:McGraw-Hill, 3695-3724.
- Önder E, Sinici I, Sönmez FM, Topçu M, Özkara HA: Identification of two novel arylsulfatase A mutation with a polymorphism as a cause of metachromatic leukodystrophy. Neurological Research. 2009, 31: 60-66. 10.1179/016164108X323762.View ArticlePubMed
- Austin JH, Armstrong D, Sheara I, McAfee D: Metachromatic form of diffuse cerebral sclerosis VI. A rapid test for the sulfatase A deficiency in metachromatic leukodystrophy (MLD) urine. Arch Neurol. 1966, 14: 259-10.1001/archneur.1966.00470090031004.View ArticlePubMed
- Lowry OH, Rosebrough NJ, Farr AL, et al.: Protein measurement with folin phenol reagent. J Biol Chem. 1951, 193: 265-275.PubMed
- Suzuki K: Enzymatic diagnosis of sphingolipidoses. Methods enzymol. 1987, 138: 727-763.View ArticlePubMed
- Dubois G, Turpin JC, Baumann N: Absence of ASA activity in the healthy father of a metchromatic leukodystrophy (MLD) patient. N Eng J Med. 1975, 293: 302-
- Jauberteau MO, Ben Younes-Chennoufi A, Rigaud M, Baumann N: IgM gammopathy and polyneuropathy react with an antigenic glycolipid present in human central nervous system. Neurosci Lett. 1989, 97: 181-184. 10.1016/0304-3940(89)90160-2.View ArticlePubMed
- Baumann N, Turpin JC, Lefevre M, Colsh B: Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationship?. Journal of physiology. 2002, 96: 301-306.PubMed
- Diez-Roux G, Ballabio A: Sulfatases and human disease. Ann Rev Genomics Hum Genet. 2005, 6: 355-79. 10.1146/annurev.genom.6.080604.162334.View Article
- Clouter-Mackie MB, Gagnier L: Spectrum of mutations in the arylsulfatase A gene in a Canadian collection including two novel frameshift mutations, a ion (C488R) and an MLD mutation (R84) in cis with a pseudodeficiency allele. Mol Genet Metab. 2003, 79: 91-8. 10.1016/S1096-7192(03)00077-5.View Article
- Maire I: Diagnostic prénatal (DPN) des maladies héréditaires du métabolisme (MHM). Biotribune. 2004, 12: 56-9.
- Polten A, Fluharty AL, Fluharty CB, Kappler J, Von Figura K, Gieselmann V: Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med. 1991, 324: 18-22. 10.1056/NEJM199101033240104.View ArticlePubMed
- Dali C, Lund AM: thérapie enzymatique substitutive par intraveineuse pour la leukodystrophie metachromatique (MLD). Congrès "Annual Clinical Genetics Meeting", Tampa, Floride (USA), 25-29 mars. 2009
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.